I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

(Susan Lanney)

Docket No.: CWRU-P01-046

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Laughlin et al.

Application No.: 10/730549

Confirmation No.: 1488

Filed: December 5, 2003

Art Unit: 1651

For:

CELL-BASED THERAPIES FOR ISCHEMIA

Examiner: L. B. Lankford

- 3

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of non-patents in accordance with 37 CFR 1.98(a)(2). A copy of the International Search Reports where these references were cited are also provided, i.e. Search Reports from PCT/US05/025854 and PCT/US05/022767.



Application No.: 10/730549 Docket No.: CWRU-P01-046

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CWRU-P01-046.

Dated: November 29, 2005

Respectfully submitted,

Ignacio Perez de la Cruz

Registration No.: 55,535 ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/730549	
11	NFORMATION	I DIS	SCLOSURE	Filing Date	December 5, 2003	•
S	TATEMENT B	3Y A	APPLICANT	First Named Inventor	Mary J. Laughlin	
				Art Unit	1651	
	(Use as many sheets as necessary)			Examiner Name	L. B. Lankford	
Sheet	1	of	1	Attorney Docket Number	CWRU-P01-046	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.¹	The state of the s			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CSSS	FINNEY, et al, "Comparison of Umbilical Cord Blood Versus Bone Marrow-Derived Endothelial Precursor Cells in Mediating Neovascularization in a NOD/SCID Hind limb injury Model", (2002)			
	СТТ	FINNEY, et al, "Umbilical Cord Blood versus Adult Bone Marrow-Derived Endothelial Precursor Cells (EPCs): In Vitro Characteristics and effectiveness in Vivo in Mediating Neovascularization after Femoral Artery Injury", Scientific Sessions. (2003).			
	CUUU	LODIE, et al, "Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals a Lack of Distinction", Tissue Engineering, vol. 8, number 5, 739-751 (2002).			
	CVVV	SCHMEISSER, et al, "Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel® under angiogenic conditions", Cardiovascular Research, vol. 49, 671-680 (2001).			
	CWWW	MA NAN, et al, "Human cord blood cells induce and angiogenesis following myocardial infarction in NOD/scid-mice", Cardiovascular Research vol. 66 no. 1, 45-54 (2005).			
	CXXX	HRISTOV, et al, "Endothelial progenitor cells: isolation and characterization", Trends in Cardiovascular Medicine, Vol. 13, no. 5, 2001-2006, (2003).			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Date Considered	
		0872406 1 DOC

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/730549

Attorney Docket No.: CWRU-P01-046

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

November 29, 2005	_ •
Date	
	/)
$1 \sim$	
	Jan)
	Signature /
	Overest experi
	Susan Lanney
Typed or printed	name of person signing Certificate
	(617) 951-7000
egistration Number if applicable	Telephone Number
	Date

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (6 References) (1 page) Supplemental Information Disclosure Statement (2 pages)

Non-Patent References: CSSS-CXXX

International Search Report from PCT/US05/025854 (3 pages) International Search Report from PCT/US05/022767 (3 pages)

Postcard Receipt